In addition, by analyzing the combined expression of lnc-IRF2-3 and lnc-KIAA1755-4, we aimed to test the above-mentioned “2-lncRNA risk model” in a heterogeneous CLL cohort. The gene discussed is IRF2; the disease is B-cell chronic lymphocytic leukemia.